Metabolic-associated fatty liver disease and major adverse cardiac events in patients with chronic coronary syndrome: a matched case–control study

[1]  M. N. Kim,et al.  Risk stratification using sarcopenia status among subjects with metabolic dysfunction‐associated fatty liver disease , 2021, Journal of cachexia, sarcopenia and muscle.

[2]  A. Han.  Association between metabolic associated fatty liver disease and osteoarthritis using data from the Korean national health and nutrition examination survey (KNHANES) , 2021, Inflammopharmacology.

[3]  L. Ji,et al.  NAFLD or MAFLD: Which Has Closer Association With All-Cause and Cause-Specific Mortality?—Results From NHANES III , 2021, Frontiers in Medicine.

[4]  T. Kawaguchi,et al.  Non-Obese MAFLD Is Associated with Colorectal Adenoma in Health Check Examinees: A Multicenter Retrospective Study , 2021, International journal of molecular sciences.

[5]  Larisse Longo,et al.  Does the risk of cardiovascular events differ between biopsy-proven NAFLD and MAFLD? , 2021, Hepatology International.

[6]  R. Gish,et al.  MAFLD and cardiovascular events: what does the evidence show? , 2021, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[7]  A. Dhawan,et al.  NAFLD to MAFLD in adults but the saga continues in children: an opportunity to advocate change.: Letter regarding "A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement". , 2021, Journal of hepatology.

[8]  Yong‐ho Lee,et al.  Metabolic Dysfunction-Associated Fatty Liver Disease and Incident Cardiovascular Disease Risk: A Nationwide Cohort Study. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[9]  Mai Mehrez,et al.  The NAFLD‐MAFLD debate: Eminence vs evidence , 2020, Liver international : official journal of the International Association for the Study of the Liver.

[10]  M. Zheng,et al.  MAFLD and risk of CKD. , 2020, Metabolism: clinical and experimental.

[11]  V. Wong,et al.  The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease , 2020, Hepatology International.

[12]  T. Kawaguchi,et al.  MAFLD identifies patients with significant hepatic fibrosis better than NAFLD , 2020, Liver international : official journal of the International Association for the Study of the Liver.

[13]  A. Kasturiratne,et al.  Outcomes of NAFLD and MAFLD: Results from a community-based, prospective cohort study , 2020, medRxiv.

[14]  Z. Goodman,et al.  From NAFLD to MAFLD: Implications of a Premature Change in Terminology , 2020, Hepatology.

[15]  Jiaofeng Huang,et al.  Comparison of MAFLD and NAFLD diagnostic criteria in real world , 2020, Liver international : official journal of the International Association for the Study of the Liver.

[16]  The Lancet Gastroenterology & Hepatology.  Redefining non-alcoholic fatty liver disease: what's in a name? , 2020, The lancet. Gastroenterology & hepatology.

[17]  S. Bollipo,et al.  What's in a name? Renaming ‘NAFLD’ to ‘MAFLD’ , 2020, Liver international : official journal of the International Association for the Study of the Liver.

[18]  V. Wong,et al.  A new definition for metabolic associated fatty liver disease: an international expert consensus statement. , 2020, Journal of hepatology.

[19]  A. Sanyal,et al.  MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. , 2020, Gastroenterology.

[20]  Marco Valgimigli,et al.  2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. , 2019, European heart journal.

[21]  E. Bugianesi,et al.  NASH in Lean Individuals , 2019, Seminars in Liver Disease.

[22]  L. Henry,et al.  NAFLD AND NASH: Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention , 2018 .

[23]  L. Henry,et al.  Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes , 2016, Hepatology.

[24]  European Association for the Study of the Liver,et al.  EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease , 2016, Obesity Facts.

[25]  C. Byrne,et al.  NAFLD: a multisystem disease. , 2015, Journal of hepatology.

[26]  Henry Völzke,et al.  Development, External Validation, and Comparative Assessment of a New Diagnostic Score for Hepatic Steatosis , 2014, The American Journal of Gastroenterology.

[27]  P. Angulo,et al.  Editorial: Noninvasive Prediction of Hepatic Steatosis , 2014, The American Journal of Gastroenterology.

[28]  H. Kim,et al.  Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. , 2010, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.